Research Success

Our success highlights from 2024-25

• We are ranked 3rd (out of 258 NHS Trusts) in the country based on income generated from our National Institute for Health Research (NIHR) portfolio, reflecting our commitment to advancing medical research and improving patient care.
• In the past financial year, we opened 106 new studies, including 38 commercial trials, marking a 52% increase from the previous year.
• We successfully recruited more than 9,000 participants and followed up more than 5,000 people, across more than 250 studies.
• NBT was awarded combined grants totalling £9.2million, with an impressive 75% success rate for full NIHR research grant submissions.
• Our efforts in commercial research have also been fruitful, with a 53% increase in the number of commercial studies opened, generating a 10% increase in gross income.
• A pilot project demonstrated the financial benefits of clinical trials, providing more than £300,000 worth of medication and medical devices that would otherwise have been funded by the NHS.
• We managed a research grant portfolio totalling £56m, including externally and internally funded grants. Most of this funding is from the prestigious National Institute for Health Research.
• We have established an Assistant Chief Nursing Officer for Research Development and Genomics, fostering future research leaders. 

Research Impact: influencing NHS & International guidelines

Professor Ed Carlton's LoDED Trial: High-sensitivity troponin tests for the early rule out of major adverse cardiac events.  

The LoDED strategy facilitates safe early discharge in more than 40% of patients with chest pain, and has been included into NHS England CQUIN: CCG14, NIHR and American Heart Association guidelines.